These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8957341)

  • 21. Castration plus nilutamide vs castration plus placebo in advanced prostate cancer. A review.
    Du Plessis DJ
    Urology; 1991; 37(2 Suppl):20-4. PubMed ID: 1992599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate.
    Smith JA; Janknegt RA; Abbou CC; de Gery A
    Eur Urol; 1997; 31 Suppl 3():25-9. PubMed ID: 9101212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
    [No Abstract]   [Full Text] [Related]  

  • 24. Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
    Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Venner PM; Tewari HD
    Prog Clin Biol Res; 1987; 243A():391-400. PubMed ID: 3116550
    [No Abstract]   [Full Text] [Related]  

  • 25. Total androgen ablation: American experience.
    Crawford ED; Nabors WL
    Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antiandrogens in monotherapy or combined therapy for treatment of advanced cancer of the prostate].
    Pavone-Macaluso M; Serretta V; Pavone C; Romano C; Daricello G
    Arch Esp Urol; 1989; 42 Suppl 2():197-205. PubMed ID: 2534783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Conference on the treatment of prostatic cancer. Munich, Germany, 2-3 November 1996].
    Lansiaux P
    Prog Urol; 1997 Dec; 7(6):1020-2. PubMed ID: 9490132
    [No Abstract]   [Full Text] [Related]  

  • 29. The place and the results of monotherapy.
    Bonnet P
    Acta Urol Belg; 1998 May; 66(2):11-5. PubMed ID: 9633120
    [No Abstract]   [Full Text] [Related]  

  • 30. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
    Decensi AU; Boccardo F; Guarneri D; Positano N; Paoletti MC; Costantini M; Martorana G; Giuliani L
    J Urol; 1991 Aug; 146(2):377-81. PubMed ID: 1856935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacology of nilutamide.
    Gaillard-Moguilewsky M; de Gery A; Ulmann A
    Cancer; 1993 Dec; 72(12 Suppl):3828-9. PubMed ID: 8252498
    [No Abstract]   [Full Text] [Related]  

  • 32. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
    Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
    Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.
    Lancet; 2000 Apr; 355(9214):1491-8. PubMed ID: 10801170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
    Labrie F; Dupont A; Bélanger A; Lacourcière Y; Monfette JE; Monfette G
    Ann Urol (Paris); 1986; 20(2):98-106. PubMed ID: 2940959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer.
    Denis L; Murphy GP
    Cancer; 1993 Dec; 72(12 Suppl):3888-95. PubMed ID: 8252511
    [No Abstract]   [Full Text] [Related]  

  • 37. Maximal androgen blockade in prostatic cancer.
    Denis L
    Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
    [No Abstract]   [Full Text] [Related]  

  • 38. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.
    Harris MG; Coleman SG; Faulds D; Chrisp P
    Drugs Aging; 1993; 3(1):9-25. PubMed ID: 8453188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.